AcneAlly | Generic Accutane Online from Dermatologists

AcneAlly is a service for patients to get prescription generic Accutane (isotretinoin) from dermatologists online, with a safety-first approach.

Phase 3 trials show tapinarof cream, safe effective for plaque psoriasis

Dermavant announces positive results from its two identical phase 3 trials investigating tapinarof cream 1% for treatment of plaque psoriasis in adult patients.

Tapinarof Cream Looks Promising for Plaque Psoriasis – MPR

Positive results were announced from two phase 3 studies evaluating tapinarof cream (Dermavant Sciences) for plaque psoriasis.

How to Approach Treatment With Biologics for Patients With Psoriasis During the COVID-19 Pandemic

Positive Phase 3 Results Results for Dermavant’s Tapinarof Cream for Plaque Psoriasis – Practical Dermatology

Dermavant Sciences shared positive results from PSOARING 1 and PSOARING 2, two identical, multi-center, randomized, vehicle-controlled, double-blind,

Mirikizumab beats secukinumab in phase 3 plaque psoriasis study

Eli Lilly’s mirikizumab demonstrates superiority over secukinumab (Cosentyx, Novartis) as a treatment for moderate-to-severe plaque psoriasis, according to recently released results from the OASIS-2 study.

MC2 Partners with EPI for Commercialization of Wynzora – Practical Dermatology

MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone

The association of psoriasis and hypertension: focusing on anti‐inflammatory therapies and immunological mechanisms

Psoriasis is a chronic skin disease characterized by recurrent inflammation, and is increasingly being recognized as a systemic inflammatory disorder, which is associated with cardiovascular events, …

Long-term data support tildrakizumab safety, user-friendliness

Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.

Meta-analysis reaffirms safety, efficacy of intermittent biologic use

According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.